Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs ProShares UltraPro S&P500 — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while ProShares UltraPro S&P500 trades at $155.73 (market cap $5.55B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 2.3× ProShares UltraPro S&P500's market cap, and Halozyme Therapeutics Inc. Common Stock is more actively traded (2,179,278 versus 2,078,694). Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and ProShares UltraPro S&P500 for 29 Days on average.
| HALO | UPRO | |
|---|---|---|
Market Cap | $12.58B | $5.55B |
Volume | 2,179,278 | 2,078,694 |
Sector | Health | Leveraged / Inverse |
52-Week High | $115.22 | $157.66 |
52-Week Low | $61.63 | $89.29 |
Typical Hold Time | 1 Days | 29 Days |
Enterprise Value | $14.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
UPRO trades at $155.73, up 0.34% today, with a bullish technical signal from moving averages and neutral oscillators. The stock faces resistance near $157 and support at $151. Key financial ratios are not available in the provided data, limiting fundamental assessment. A dividend of $0.27 is scheduled for September 2026.
The outlook is cautiously optimistic due to bullish technical trends, but the absence of fundamental metrics like P/E and ROE increases reliance on market sentiment. Risks include S&P 500 volatility and profit growth concerns highlighted in recent news. Investors should seek updated financials for a complete view.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
